Treatment Options for Resistant Kawasaki Disease.
Paediatr Drugs
; 20(1): 59-80, 2018 Feb.
Article
em En
| MEDLINE
| ID: mdl-29101553
ABSTRACT
"Resistant" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable. We review the current evidence to guide treatment of resistant Kawasaki disease. Given the relative rarity, there are few trial data, and studies tend to be small and methodologically heterogeneous, making interpretation difficult and limiting generalisability. The literature on resistant Kawasaki disease should be interpreted with reference to current expert consensus guidelines.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulinas Intravenosas
/
Síndrome de Linfonodos Mucocutâneos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article